Bilirubin and progression of nephropathy in type 2 diabetes: A post hoc analysis of RENAAL with independent replication in IDNT

Diabetes

Volumn 63, Issue 8, 2014, Pages 2845-2853

  Riphagen, Ineke J ^a   Deetman, Petronella E ^a   Bakker, Stephan J L ^a   Navis, Gerjan ^a   Cooper, Mark E ^b   Lewis, Julia B ^c   De Zeeuw, Dick ^d   Heerspink, Hiddo J Lambers ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BILIRUBIN; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TETRAZOLES;

EID: 84905044209     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1652     Document Type: Article

References (32)

1. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl. 1):S11-S63
2. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288:F778-F784
3. Lin JP, Vitek L, Schwertner HA Serum bilirubin and genes controlling bil-irubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56:1535-1543
4. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 2012; 3:55
5. Fujii M, Inoguchi T, Sasaki S., et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78:905-919
6. Inoguchi T, Sasaki S, Kobayashi K., Takayanagi R, Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007; 298:1398-1400
7. Zelle DM, Deetman N, Alkhalaf A., Navis G, Bakker SJ. Support for a protective effect of bilirubin on diabetic nephropathy in humans. Kidney Int 2011; 79: 686-687
8. Fukui M, Tanaka M, Shiraishi E., et al. Relationship between serum bili-rubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008; 74: 1197-1201
9. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1:328-335
10. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869
11. Rodby RA, Rohde RD, Clarke W.R., et al.; Collaborative Study Group. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15:487-497
12. Lewis EJ, Hunsicker LG, Clarke W.R., et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860
13. Mohanram A, Zhang Z, Shahinfar S., Lyle PA, Toto RD. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008; 73:630-636
14. Slagman MC, Sinkeler SJ, Hemmelder M.H., et al. Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant 2010; 25:3256-3260
15. Robles NR, Angulo E, Grois J., Barquero A. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 2004; 26:399-404
16. Packham DK, Alves TP, Dwyer J.P., et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59:75-83
17. Levey AS, Bosch JP, Lewis J.B., Greene T., Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glo-merular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470
18. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40:405-412
19. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19:257-267
20. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-1070
21. Stanton RC. Oxidative stress and diabetic kidney disease. Curr Diab Rep 2011; 11:330-336
22. Koya D, Hayashi K, Kitada M., Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003; 14(Suppl. 3):S250-S253
23. Abraham NG, Cao J, Sacerdoti D., Li X, Drummond G. Heme oxygenase: the key to renal function regulation. Am J Physiol Renal Physiol 2009; 297:F1137-F1152
24. Elmarakby AA, Faulkner J, Baban B., Sullivan JC. Induction of hemeox-ygenase-1 reduces renal oxidative stress and inflammation in diabetic spontaneously hypertensive rats. Int J Hypertens 2012; 2012:957235
25. Barbagallo I, Galvano F, Frigiola A., et al. Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal 2013; 18:507-521
26. Fevery J. Bilirubin in clinical practice: a review. Liver Int 2008; 28:592-605
27. Mrug M, Stopka T, Julian B.A., Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310-2314
28. Freudenthaler SM, Schreeb K, Körner T, Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999; 29: 816-823
29. Sassa S, Kappas A, Bernstein S.E., Alvares AP. Heme biosynthesis and drug metabolism in mice with hereditary hemolytic anemia. Heme oxygenase induction as an adaptive response for maintaining cytochrome P-450 in chronic hemolysis. J Biol Chem 1979; 254:729-735
30. Mashitani T, Hayashino Y, Okamura S., Tsujii S, Ishii H. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 5]). Diabetes Care 2014; 37:252-258
31. Verduijn M, Siegerink B, Jager K.J., Zoccali C., Dekker FW. Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrol Dial Transplant 2010; 25:1394-1398
32. McArdle PF, Whitcomb BW, Tanner K, Mitchell B.D., Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012; 12:16